

INDEX

Contents	Page No.
LIST OF FIGURES.....	XIII-XXIII
LIST OF SCHEMES.....	xxiv
LIST OF TABLES.....	xxv
LIST OF ABBREVIATIONS.....	XXVI-XXVII
PREFACE.....	xxix-xxx
CHAPTER-1 INTRODUCTION	1-16
1.1. INFLAMMATION.....	1
1.2. ANTI-INFLAMMATORY MEDICATIONS AND THEIR LIMITATIONS	2
1.3. ARACHIDONIC ACID PATHWAY.....	3
<i>1.3.1. The Cyclooxygenase (COX) pathway.....</i>	<i>3</i>
<i>1.3.2. The Lipooxygenase (LOX) pathway.....</i>	<i>6</i>
<i>1.3.3. Lipoxins.....</i>	<i>6</i>
1.4. DUAL COX-2/5-LOX INHIBITION: A PROMISING APPROACH FOR EFFECTIVE INFLAMMATION MANAGEMENT	7
1.5. UNMET NEED AND RESEARCH OPPORTUNITY: LACK OF APPROVED DUAL COX-2/5-LOX INHIBITORS.....	9
1.6. ROLE OF DUAL COX-2/5-LOX INHIBITION IN VARIOUS DISEASES.....	10
<i>1.6.1. Role of Dual COX-2/5-LOX Inhibition in Cardiovascular Diseases.....</i>	<i>10</i>
<i>1.6.2. Role of Dual COX-2/5-LOX Inhibition in Cancer</i>	<i>11</i>
<i>1.6.3. Role of Dual COX-2/5-LOX Inhibition in Asthma and Chronic Obstructive Pulmonary Disease (COPD)</i>	<i>14</i>
<i>1.6.4. Role of Dual COX-2/5-LOX Inhibition in Rheumatoid Arthritis and Osteoarthritis</i>	<i>15</i>
<i>1.6.5. Role of Dual COX-2/5-LOX Inhibition in Metabolic Syndrome and Diabetes:.....</i>	<i>15</i>
<i>1.6.6. Role of Dual COX-2/5-LOX Inhibition in Neurodegenerative Diseases:</i>	<i>15</i>
<i>1.6.7. Role of Dual COX-2/5-LOX Inhibition in Chronic Pain Conditions:.....</i>	<i>15</i>

Contents	Page No.
CHAPTER-2 REVIEW OF LITERATURE	17-43
2.1. 1,2,4-TRIAZINE AS ANTI-INFLAMMATORY AGENTS.....	17
2.2. 1,3,4-OXADIAZOLE AS ANTI-INFLAMMATORY AGENTS.....	26
2.3. BENZHYDRYLPIPERAZINE AS ANTI-INFLAMMATORY AGENTS.....	36
CHAPTER-3 RATIONALE, OBJECTIVE AND PLAN OF WORK	45-53
3.1. Rationale.....	45
3.2. Objectives.....	45
3.3. Plan Of Work.....	52
CHAPTER-4 EXPERIMENTAL	55-70
4.1. Computational studies.....	54
4.1.1. <i>Molecular docking studies</i>	54
4.1.2. <i>Molecular dynamics simulation study</i>	55
4.1.3. <i>Drug-likeness determination by Qikprop module</i>	56
4.2. Synthesis of novel compound	56
4.2.1. <i>Chemicals and reagents</i>	56
4.2.2. <i>Synthesis of novel compounds series-I</i>	56
4.2.3. <i>Synthesis of novel compound series-II</i>	58
4.3. Characterization of synthesized derivatives.....	61
4.4. Pharmacological/biological assays.....	62
4.4.1. <i>In vitro biological assay</i>	62
4.4.2. <i>In vivo biological assay</i>	64
4.4.3. <i>In vitro anti-cancer activity</i>	68
4.4.4. <i>Anti-cancer activity in in vivo model</i>	69
4.4.5. <i>Pharmacokinetic studies</i>	70
CHAPTER-5 RESULTS AND DISCUSSIONS	71-138
5.1. CHAPTER-5 (PART-1).....	73

Contents	Page No.
<i>NOVEL COMPOUNDS SERIES-I</i>	73
5.1.1. <i>In silico studies</i>	71
5.1.2. <i>Chemistry</i>	77
5.1.3. <i>Biological screening</i>	84
5.2. <i>PART-II</i>	98
<i>NOVEL COMPOUNDS SERIES-II</i>	98
5.2.1. <i>Computational studies and design considerations</i>	95
5.2.2. <i>Chemistry</i>	104
5.2.3. <i>Biological screening</i>	113
CHAPTER-6 SUMMARY AND CONCLUSION	139-144
CHAPTER-7 REFERENCES	145-155
CHAPTER-8 APPENDIX	157-195
LIST OF RESEARCH PAPERS AND PRESENTATIONS	197-199
